Lois E. Shepherd
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Breast Cancer Treatment Studies 36
- Cancer Genomics and Diagnostics 10
-
- Lymphoma Diagnosis and Treatment 46
- Co-authors
- Dongsheng Tu (37 shared papers)Kathleen Pritchard (51 shared papers)Malcolm J. Moore (2 shared papers)Daniel J. Sargent (5 shared papers)Richard M. Goldberg (4 shared papers)James N Ingle (31 shared papers)Michael J. E. Palmer (10 shared papers)Charles Alan Schiffer (11 shared papers)
- Journals
- Journal of Clinical Oncology (35 papers)Blood (26 papers)Breast Cancer Research and Treatment (19 papers)New England Journal of Medicine (10 papers)Clinical Cancer Research (9 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Lois E. Shepherd
213 papers receiving 22.5k citations
Lois E. Shepherd's Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 6.1k
- Oncology 10.7k
- Pathology and Forensic Medicine 5.6k
- Genetics 1.6k
- Hematology 1.6k
Countries citing papers authored by Lois E. Shepherd
This map shows the geographic impact of Lois E. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lois E. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lois E. Shepherd more than expected).
Fields of papers citing papers by Lois E. Shepherd
This network shows the impact of papers produced by Lois E. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lois E. Shepherd. The network helps show where Lois E. Shepherd may publish in the future.
Co-authors
The 25 scholars most cited alongside Lois E. Shepherd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 219 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer Hit paper breakdown → | 2008 | 3052 |
| 2 | Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer Hit paper breakdown → | 2003 | 1798 |
| 3 | A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer Hit paper breakdown → | 2003 | 1473 |
| 4 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Hit paper breakdown → | 2009 | 1150 |
| 5 | All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Hit paper breakdown → | 1997 | 928 |
| 6 | Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 Hit paper breakdown → | 2005 | 908 |
| 7 | Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia Hit paper breakdown → | 2000 | 820 |
| 8 | Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? Hit paper breakdown → | 2004 | 819 |
| 9 | A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients Hit paper breakdown → | 2001 | 783 |
| 10 | CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Hit paper breakdown → | 2011 | 653 |
| 11 | 1998 | 489 | |
| 12 | 2006 | 415 | |
| 13 | Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 Hit paper breakdown → | 2014 | 382 |
| 14 | 1998 | 330 | |
| 15 | 2011 | 308 | |
| 16 | 2019 | 306 | |
| 17 | 2004 | 263 | |
| 18 | 2012 | 256 | |
| 19 | 2005 | 253 | |
| 20 | 2006 | 247 |
About Lois E. Shepherd
Lois E. Shepherd is a scholar working on Cancer Research, Pathology and Forensic Medicine, Oncology, Hematology and Genetics, having authored 219 papers that have together received 23.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (46 papers), Breast Cancer Treatment Studies (36 papers), Estrogen and related hormone effects (19 papers), Chronic Lymphocytic Leukemia Research (16 papers), Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (15 papers), Multiple Myeloma Research and Treatments (14 papers) and Cancer Genomics and Diagnostics (10 papers). The work is most often cited by research in Cancer Research (6.1k citations), Oncology (10.7k citations), Pathology and Forensic Medicine (5.6k citations), Genetics (1.6k citations) and Hematology (1.6k citations). Lois E. Shepherd has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Dongsheng Tu, Kathleen Pritchard, Malcolm J. Moore, Daniel J. Sargent, Richard M. Goldberg, James N Ingle, Michael J. E. Palmer, Charles Alan Schiffer, Edith A. Perez and Frederick R. Appelbaum. Their work appears in journals such as Journal of Clinical Oncology, Blood, Breast Cancer Research and Treatment, New England Journal of Medicine and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.